SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 8/28/02 Intermune Inc 8-K:5,7 8/28/02 2:41K Merrill Corp/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 20K 2: EX-99.1 Miscellaneous Exhibit HTML 20K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13
or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28, 2002
INTERMUNE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State of jurisdiction)
|
94-3296648 |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
3280 Bayshore Boulevard
Brisbane, CA 94005
(Address
and registrant’s principal executive offices and zip code)
Registrant’s telephone number, including area code: (415) 466-2200
Item 5. Other Events
On August 28, 2002, InterMune, Inc. issued a press release entitled “InterMune Announces Phase III Data Demonstrating Survival Benefit of Actimmune in IPF,” announcing the Phase III clinical trial results of Actimmune (interferon gamma-1b) in the treatment of idiopathic pulmonary fibrosis. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits.
Number |
|
Description |
99.1 |
|
Press Release entitled “InterMune Announces Phase III Data Demonstrating Survival Benefit of Actimmune in IPF,” dated August 28, 2002. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
INTERMUNE, INC. |
|
|
|
|
|
|
|
|
|
Dated: August 28, 2002 |
|
By: |
/s/ Bradley R. Scates |
|
|
|
Bradley R. Scates |
|
|
|
Vice President, Finance |
|
|
|
|
3
Number |
|
Description |
99.1 |
|
Press Release entitled “InterMune Announces Phase III Data Demonstrating Survival Benefit of Actimmune in IPF,” dated August 28, 2002. |
4
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period End: | 8/28/02 | None on these Dates | ||
List all Filings |